Clinical Trials · NCT00191321
Teriparatide Use in Hip Replaced Subjects
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 60
- Start date
- Jul 2004
- Locations
- 11 sites, Italy
- Primary endpoint
- Effect of Teriparatide (20 mcg/day for 18 months ) on bone turnover markers: CTx, PINP and BSAP